BioCryst to Report Second Quarter 2022 Financial Results on August 4
July 21 2022 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that
the company will report its second quarter 2022 financial results
Thursday, August 4, 2022.
BioCryst management will host a conference call
and webcast at 8:30 a.m. ET that day to discuss the financial
results and provide a corporate update.
The live call may be accessed by dialing
866-374-5140 for domestic callers and 404-400-0571 for
international callers and using conference ID 68509725#. A live
webcast of the call and any slides will be available online at the
investors section of the company website at www.biocryst.com. A
replay of the call will be available on the company website.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule
medicines that treat rare diseases in which significant unmet
medical needs exist and an enzyme plays a key role in the
biological pathway of the disease. Oral, once-daily ORLADEYO®
(berotralstat) is approved in the United States and multiple global
markets. BioCryst has several ongoing development programs
including BCX9930, an oral Factor D inhibitor for the treatment of
complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva, and
galidesivir, a potential treatment for Marburg virus disease and
yellow fever. RAPIVAB® (peramivir injection) is approved in the
U.S. and multiple global markets, with post-marketing commitments
ongoing. For more information, please visit the company’s website
at www.biocryst.com.
BCRXW
Contact:InvestorsJohn Bluth+1
919 859 7910jbluth@biocryst.com
MediaCatherine Collier Kyroulis+1 917 886
5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024